Revolution Medicines, Inc. develops targeted oncology therapies for patients with RAS-addicted cancers. Company news centers on its RAS(ON) inhibitor pipeline, including daraxonrasib, a RAS(ON) multi-selective inhibitor, and selective programs such as elironrasib, zoldonrasib and RMC-5127.
Recurring updates cover clinical data in pancreatic ductal adenocarcinoma, non-small cell lung cancer and other RAS-mutant solid tumors, presentations at oncology meetings, scientific publications, regulatory interactions and trial-stage progress. Revolution Medicines also reports quarterly financial results, financing activity and corporate progress tied to research and development, potential commercialization planning and its broader RAS(ON) discovery platform.
Revolution Medicines (Nasdaq:RVMD) announced the closing of a public offering of 6,666,666 shares at $45.00 each, totaling gross proceeds of $300 million. This includes 869,565 additional shares sold after underwriters exercised their option. The offering was managed by J.P. Morgan, Cowen, SVB Leerink, and Guggenheim Securities, with prior SEC registration on February 3, 2021. Funds will support the company’s focus on developing targeted therapies for RAS-addicted cancers.
Revolution Medicines (Nasdaq: RVMD) has priced its underwritten public offering of 5,797,101 shares of common stock at $45.00 per share, aiming to raise approximately $260.9 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 869,565 shares. The closing of this offering is anticipated on February 8, 2021, pending customary conditions. This fundraising initiative is aimed at advancing the company's pipeline focused on targeted therapies for RAS-addicted cancers.
Revolution Medicines (Nasdaq: RVMD) has initiated an underwritten public offering of 4,000,000 shares of common stock, with an option for underwriters to purchase an additional 600,000 shares.
Major banks including J.P. Morgan, Cowen, SVB Leerink, and Guggenheim Securities are serving as joint book-running managers for this offering. The offering is made through a registered prospectus filed with the SEC. This press release does not qualify as an offer to sell or buy these securities in jurisdictions where it is unlawful prior to registration.
Revolution Medicines (Nasdaq: RVMD) announced that CEO Mark A. Goldsmith will present at the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. During the presentation, scheduled for January 12 at 5:20 p.m. Eastern, Dr. Goldsmith will discuss the advancement of two first-in-class RAS(ON) Inhibitor programs into IND-enabling development. He will also provide updates on three RAS Companion Inhibitors: RMC-4630, RMC-5552, and the newly introduced RMC-5845. The presentation will be available via webcast on the company's website.
Revolution Medicines (RVMD) provided an update on its RMC-4630 programs for RAS-addicted cancers, announcing selected Phase 2 doses for both monotherapy and combination therapies. Financial results for Q3 2020 show revenue of $12.7 million, up from $12.5 million in Q3 2019. However, R&D expenses rose to $34.9 million, leading to a net loss of $27.2 million, compared to a loss of $12.8 million in the previous year. The company has positioned itself as a leader in RAS-targeted therapies and has extended its clinical collaborations to enhance its drug development pipeline.
Revolution Medicines (RVMD) recently presented interim data from its Phase 1b/2 trial of RMC-4630 combined with cobimetinib at the EORTC-NCI-AACR Symposium. The dual intermittent dosing strategy showed tolerable adverse effects and exceeded target plasma exposures, indicating potential clinical activity in KRAS-mutated colorectal cancers. Additionally, a new collaboration with AstraZeneca aims to explore RMC-4630's combination with a KRAS-targeting drug. Preliminary results suggest anti-tumor activity, with tumor volume reduction in three of seven patients receiving the highest dose.
Revolution Medicines, Inc. (NASDAQ: RVMD) announced that interim data from its Phase 1b/2 trial, RMC-4630-02, will be presented at the EORTC-NCI-AACR 32nd Symposium on October 24-25, 2020. This trial evaluates the safety and efficacy of RMC-4630 in combination with cobimetinib for patients with relapsed/refractory solid tumors. The company aims to explore drug combinations as a strategy to overcome resistance mechanisms in RAS-addicted cancers. The presentation will focus on dosing regimens and pharmacokinetic findings.
Revolution Medicines (Nasdaq: RVMD) presented groundbreaking data on its KRASG12D(ON) inhibitors, showcasing their ability to induce tumor regressions in a preclinical human pancreatic cancer model. This marks the first public demonstration of anti-tumor activity for these inhibitors, emphasizing their potential in treating cancers associated with the KRASG12D mutation, which is significant given the lack of approved therapies targeting this mutation. The KRASG12D(ON) program is entering lead optimization after showing effective dose-dependent anti-tumor results.
Revolution Medicines, Inc. (Nasdaq: RVMD) announced that CEO Mark A. Goldsmith will present at the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, 2020. His presentation is scheduled for September 14 at 11:00 a.m. Eastern Time. A live webcast will be accessible through the company's website, with a replay available post-conference. Revolution Medicines focuses on precision oncology, developing targeted therapies for RAS-addicted cancers, including RMC-4630 and RMC-5552, aimed at inhibiting critical cancer signaling pathways.
Revolution Medicines (Nasdaq: RVMD) will participate in the 2nd Annual RAS-Targeted Drug Development Conference from September 14-16, 2020. Key presentations include:
- Title: Approaches to Inhibiting RAS Driven Tumors Beyond KRAS G12C
Presenter: Steve Kelsey, M.D.
Date: September 16, 2020, 9:00 a.m. Eastern - Title: Empowering Combination Strategies to Target RAS Mutant Cancers
Participant: Jan Smith, Ph.D.
Date: September 16, 2020, 4:30 p.m. Eastern - Workshop: Navigating the Future Potential of Combination Strategies
Co-Leader: Jan Smith, Ph.D.
Date: September 14, 2020, 11:30 a.m. Eastern